{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:18:18Z","timestamp":1770221898397,"version":"3.49.0"},"reference-count":82,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","primarycare.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care: Clinics in Office Practice"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.pop.2014.08.002","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T05:40:53Z","timestamp":1412055653000},"page":"765-778","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Renin-Angiotensin-Aldosterone System Inhibition"],"prefix":"10.1016","volume":"41","author":[{"given":"Kelly","family":"Mercier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Biederman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pop.2014.08.002_bib1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/1056-8727(95)80028-D","article-title":"Current concepts of renal hemodynamics in diabetes","volume":"9","author":"Anderson","year":"1995","journal-title":"J\u00a0Diabet Complications"},{"key":"10.1016\/j.pop.2014.08.002_bib2","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1681\/ASN.2005080872","article-title":"Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes","volume":"17","author":"Sochett","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.pop.2014.08.002_bib3","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1161\/hy1101.099502","article-title":"Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy","volume":"38","author":"Svensson","year":"2001","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.pop.2014.08.002_bib4","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure","volume":"42","author":"Chovanian","year":"2003","journal-title":"Hypertension"},{"issue":"13","key":"10.1016\/j.pop.2014.08.002_bib5","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJM199304013281303","article-title":"Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents","volume":"328","author":"Materson","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2014.08.002_bib6","first-page":"141","article-title":"Maximizing cardiorenal benefit in the management of hypertension: achieve blood pressure goals","volume":"1","author":"Bakris","year":"1999","journal-title":"J\u00a0Clin Hypertens"},{"issue":"7404","key":"10.1016\/j.pop.2014.08.002_bib7","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1136\/bmj.326.7404.1427","article-title":"Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials","volume":"326","author":"Law","year":"2003","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.pop.2014.08.002_bib8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00003495-200262030-00003","article-title":"Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats","volume":"62","author":"Sica","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/j.pop.2014.08.002_bib9","first-page":"592","article-title":"Overview of patient compliance with medication dosing: a literature review","volume":"6","author":"Greenberg","year":"1984","journal-title":"Clin Ther"},{"key":"10.1016\/j.pop.2014.08.002_bib10","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","year":"2002","journal-title":"JAMA"},{"issue":"23","key":"10.1016\/j.pop.2014.08.002_bib11","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.pop.2014.08.002_bib12","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.2337\/dc11-s246","article-title":"Diuretic treatment of hypertension","volume":"34","author":"Grossman","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pop.2014.08.002_bib13","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1001\/jama.289.16.2073","article-title":"Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial","volume":"289","author":"Black","year":"2003","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.pop.2014.08.002_bib14","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.2337\/diacare.27.7.1688","article-title":"The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes","volume":"27","author":"Rubio-Guerra","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pop.2014.08.002_bib15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1470-2045(10)70106-6","article-title":"Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pop.2014.08.002_bib16","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.110.007336","article-title":"Use of angiotensin receptor blockers and the risk of cancer","volume":"123","author":"Pasternak","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pop.2014.08.002_bib17","unstructured":"US Food and Drug Administration. FDA drug safety communication: no increase in risk of cancer with certain blood pressure drugs\u2013angiotensin receptor blockers (ARBs). June 2, 2011. Available at: http:\/\/www.fda.gov\/Drugs\/%20DrugSafety\/ucm257516.htm. Accessed on January 7, 2014."},{"key":"10.1016\/j.pop.2014.08.002_bib18","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2014.08.002_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2014.08.002_bib20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2014.08.002_bib21","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2004110919","article-title":"Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations","volume":"16","author":"Pohl","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.pop.2014.08.002_bib22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood- pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2014.08.002_bib23","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2014.08.002_bib24","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"issue":"Supp 2","key":"10.1016\/j.pop.2014.08.002_bib25","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1681\/ASN.2005121337","article-title":"Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression","volume":"4","author":"Strippoli","year":"2006","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.pop.2014.08.002_bib26","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2014.08.002_bib27","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2014.08.002_bib28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","author":"HOPE Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2014.08.002_bib29","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria","volume":"349","author":"The Euclid study group","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2014.08.002_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes","volume":"151","author":"Bilous","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pop.2014.08.002_bib31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361.1","author":"Mauer","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pop.2014.08.002_bib32","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/archinternmed.2011.16","article-title":"Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications cohort","volume":"171","author":"de Boer","year":"2011","journal-title":"Arch Intern Med"},{"issue":"9739","key":"10.1016\/j.pop.2014.08.002_bib33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2014.08.002_bib34","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"7274","key":"10.1016\/j.pop.2014.08.002_bib35","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.321.7274.1440","article-title":"Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study","volume":"321","author":"Mogensen","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.pop.2014.08.002_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both in patients at high vascular risk (the ONTARGET study): a multicenter, randomized, double-blind, controlled trial","volume":"372","author":"The ONTARGET Investigators","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2014.08.002_bib37","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2014.08.002_bib38","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"Parving","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.pop.2014.08.002_bib39","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.pop.2014.08.002_bib40","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2310\/JIM.0b013e31816d78e9","article-title":"Effects of additive therapy with spironolactone on proteinuria in diabetic patients already on ACE inhibitor or ARB therapy: results of a randomized, placebo-controlled, double-blind, crossover trial","volume":"56","author":"Saklayen","year":"2008","journal-title":"J\u00a0Investig Med"},{"issue":"12","key":"10.1016\/j.pop.2014.08.002_bib41","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.pop.2014.08.002_bib42","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1097\/HJH.0b013e32833d4c99","article-title":"Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system","volume":"28","author":"Alvarez-Alvarez","year":"2010","journal-title":"J\u00a0Hypertens"},{"issue":"11 Pt 1","key":"10.1016\/j.pop.2014.08.002_bib43","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"issue":"2","key":"10.1016\/j.pop.2014.08.002_bib44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.7326\/0003-4819-135-2-200107170-00007","article-title":"Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data","volume":"135","author":"Jafar","year":"2001","journal-title":"Ann Intern Med"},{"issue":"21","key":"10.1016\/j.pop.2014.08.002_bib45","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.pop.2014.08.002_bib46","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"9136","key":"10.1016\/j.pop.2014.08.002_bib47","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0140-6736(98)04433-X","article-title":"Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy","volume":"352","author":"Ruggenenti","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2014.08.002_bib48","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy","volume":"349","author":"The GISEN Group","year":"1997","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pop.2014.08.002_bib49","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"13","key":"10.1016\/j.pop.2014.08.002_bib50","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease","volume":"330","author":"Klahr","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2014.08.002_bib51","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.105.538132","article-title":"Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study","volume":"112","author":"Arnlov","year":"2005","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.pop.2014.08.002_bib52","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/archinte.160.8.1093","article-title":"The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus","volume":"160","author":"Valmadrid","year":"2000","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.pop.2014.08.002_bib53","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s11255-011-0110-z","article-title":"Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial","volume":"44","author":"Lizakowski","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.pop.2014.08.002_bib54","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s11255-011-9991-0","article-title":"Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease","volume":"44","author":"Moriyama","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.pop.2014.08.002_bib55","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","article-title":"Aldosterone blockade: an emerging strategy for abrogating progressive renal disease","volume":"119","author":"Epstein","year":"2006","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.pop.2014.08.002_bib56","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.pop.2014.08.002_bib57","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.jacc.2003.10.073","article-title":"Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial","volume":"43","author":"Lonn","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8875","key":"10.1016\/j.pop.2014.08.002_bib58","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","author":"Acute Infarction Ramipril Efficacy (AIRE) Study Investigators","year":"1993","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.pop.2014.08.002_bib59","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A\u00a0clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"9311","key":"10.1016\/j.pop.2014.08.002_bib60","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.pop.2014.08.002_bib61","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1161\/01.CIR.0000146819.43235.A9","article-title":"Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials","volume":"110","author":"Young","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pop.2014.08.002_bib62","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pop.2014.08.002_bib63","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jacc.2005.09.055","article-title":"The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)","volume":"47","author":"McMurray","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.pop.2014.08.002_bib64","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/eurheartj\/ehq522","article-title":"Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with systolic dysfunction","volume":"32","author":"Solomon","year":"2011","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.pop.2014.08.002_bib65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"The SOLVD Investigators","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.pop.2014.08.002_bib66","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N\u00a0Engl J Med"},{"issue":"5 Pt 1","key":"10.1016\/j.pop.2014.08.002_bib67","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1161\/01.CIR.88.5.2277","article-title":"Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators","volume":"88","author":"Konstam","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.pop.2014.08.002_bib68","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2014.08.002_bib69","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2014.08.002_bib70","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pop.2014.08.002_bib71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1054\/jcaf.2003.22","article-title":"Effect of Valsartan on hospitalization: results from Val-HeFT","volume":"9","author":"Carson","year":"2003","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.pop.2014.08.002_bib72","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.pop.2014.08.002_bib73","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pop.2014.08.002_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.pop.2014.08.002_bib75","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.pop.2014.08.002_bib76","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"9287","key":"10.1016\/j.pop.2014.08.002_bib77","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet"},{"issue":"9644","key":"10.1016\/j.pop.2014.08.002_bib78","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial","volume":"372","author":"The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pop.2014.08.002_bib79","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1056\/NEJMoa0804593","article-title":"Telmisartan to prevent recurrent stroke and cardiovascular events","volume":"359","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.pop.2014.08.002_bib80","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","article-title":"Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES)","volume":"36","author":"Schrader","year":"2005","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.pop.2014.08.002_bib81","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1161\/01.STR.0000075777.18006.89","article-title":"The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors","volume":"34","author":"Schrader","year":"2003","journal-title":"Stroke"},{"issue":"7","key":"10.1016\/j.pop.2014.08.002_bib82","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/STROKEAHA.113.001022","article-title":"Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial","volume":"44","author":"Hornslien","year":"2013","journal-title":"Stroke"}],"container-title":["Primary Care: Clinics in Office Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454314000888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454314000888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,29]],"date-time":"2018-09-29T00:52:45Z","timestamp":1538182365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095454314000888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":82,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0095454314000888"],"URL":"https:\/\/doi.org\/10.1016\/j.pop.2014.08.002","relation":{},"ISSN":["0095-4543"],"issn-type":[{"value":"0095-4543","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin-Angiotensin-Aldosterone System Inhibition","name":"articletitle","label":"Article Title"},{"value":"Primary Care: Clinics in Office Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pop.2014.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}